STOCK TITAN

PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026

(Neutral)
(Very Positive)
Tags
earnings date

PTC Therapeutics (NASDAQ: PTCT) will report first quarter 2026 financial results on Thursday, May 7, 2026 at 4:30 p.m. ET via a live webcast and conference call. The company will provide a business update and outlook during the event.

A replay will be available on the company's Investors "Events & Presentations" page for 30 days; phone participation requires advance registration for dial-in details.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction – PTCT

+0.31%
+0.31% Session close to close

In the Apr 22 session, PTCT gained 0.31%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement schedules PTC Therapeutics’ Q1 2026 earnings webcast for May 7, 2026 at 4:30 p.m. ...
Analysis

This announcement schedules PTC Therapeutics’ Q1 2026 earnings webcast for May 7, 2026 at 4:30 p.m. ET, mirroring the prior pattern of pre-announced earnings dates. Historically, a similar notice on Feb. 5, 2026 coincided with a modest -2.1% move. Investors may focus on how upcoming results compare to strong 2025 metrics like $1.731B in total revenue and $1.945B in year-end cash, alongside recent insider activity.

Key Figures

Earnings call date: May 7, 2026 Total 2025 revenue: $1.731B 2025 product & royalty revenue: $831M +5 more
8 metrics
Earnings call date May 7, 2026 Scheduled Q1 2026 results webcast at 4:30 p.m. ET
Total 2025 revenue $1.731B Full-year 2025 results previously reported
2025 product & royalty revenue $831M Full-year 2025
Year-end 2025 cash $1.945B Cash balance at end of 2025
Evrysdi royalty upfront $240M Royalty sale upfront payment
Evrysdi milestones $60M Potential additional royalty sale milestones
2025 net income $682.6M Full-year 2025 net income driven by collaboration payment
Short interest 12.36% Reported short interest as a percent of float

Previous Earnings date Reports

1 past event · Latest: Feb 05 (Neutral)
Same Type Pattern 1 events
Date Event Sentiment 24h Move Catalyst
Feb 05 Earnings date set Neutral -2.1% Announcement of date and time for Q4 and full-year 2025 results webcast.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The prior earnings date announcement saw a modest negative move, suggesting that earnings scheduling releases for PTCT have not historically been clear positive catalysts.

Recent Company History

Over recent months, PTC Therapeutics reported strong 2025 financials, including total revenues of $1.731B and year-end cash of $1.945B, alongside a profitable Novartis collaboration. It has also issued multiple inducement equity grants and added an experienced biotech banker to its board. The current announcement simply sets the May 7, 2026 webcast date for Q1 2026 results, mirroring the prior pattern where an earnings date notice on Feb. 5, 2026 preceded full-year 2025 results.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

WARREN, N.J., April 22, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2026 financial results and provide an update on the company's business and outlook on Thursday, May 7, 2026, at 4:30 p.m. ET.

To access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available on the PTC website for 30 days following the event. To participate via phone, please register in advance here to receive dial-in details.

ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Instagram and Facebook.

For more information, please contact:

Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri@ptcbio.com

Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-7-2026-302749730.html

SOURCE PTC Therapeutics, Inc.

FAQ

When will PTC Therapeutics (PTCT) report Q1 2026 results and how can I watch?

PTC Therapeutics will report Q1 2026 results on May 7, 2026 at 4:30 p.m. ET. According to the company, the event will be available via a live webcast on the Investors "Events & Presentations" page and by phone with prior registration.

Will PTC Therapeutics (PTCT) provide a replay of the May 7, 2026 webcast?

Yes, a replay will be available for 30 days after the event. According to the company, the webcast replay can be accessed on the Investors "Events & Presentations" page on the PTC website for one month following the live presentation.

How can investors participate by phone in the PTCT May 7, 2026 earnings call?

Investors can join by phone after registering in advance to receive dial-in details. According to the company, registrants will get required dial-in and access information to participate in the conference call live.

What will PTC Therapeutics (PTCT) cover during the Q1 2026 call on May 7?

The company will report first quarter financial results and provide a business update and outlook. According to the company, management will discuss operational developments and the near-term commercial and financial outlook during the webcast and call.